Krystal Biotech, Inc. is a commercial-stage company focused on developing genetic medicines to address high unmet medical needs. Their mission is to develop and deliver redosable gene therapies for the treatment of severe, life-threatening, or rare diseases that have limited or no approved therapies. Krystal's first commercial product, VYJUVEK, is the pioneering redosable gene therapy designed to treat dystrophic epidermolysis bullosa. The company is advancing an integrated pipeline of genetic therapies aimed at correcting the root causes of serious and rare genetic diseases. Krystal utilizes a novel therapeutic platform based on a modified and engineered HSV-1 vector that is replication-defective and non-integrating, ensuring a safe and effective delivery of gene therapies. With two GMP facilities, Krystal is committed to the manufacturing and commercialization of transformative genetic medicines.
November 23
The RGTC promotes Vyjuvek to healthcare professionals for DEB treatment while building key relationships.
πΊπΈ United States β Remote
π΅ $185k - $215k / year
β° Full Time
π Senior
π΄ Lead
πΆβπ«οΈ Therapist
November 23
Serve as the Regional Gene Therapy Consultant promoting Vyjuvek for DEB treatment in the field. Drive product awareness and build trust with stakeholders in the Dermatology Community.
πΊπΈ United States β Remote
π΅ $185k - $215k / year
β° Full Time
π Senior
π΄ Lead
πΆβπ«οΈ Therapist
November 1
Lead commercial efforts for gene therapy at Krystal Biotech in France.